Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat

Dominique P. Germain(Université de Versailles Saint-Quentin-en-Yvelines), Raphael Schiffmann(Baylor Scott & White Health), William R. Wilcox(Emory University), Elizabeth Ludington(Université Paris-Saclay), Fatih Süheyl Ezgü(Gazi University), Derralynn Hughes(Royal Free London NHS Foundation Trust), Roser Torrá(Hospital de Sant Pau), Claudio Feliciani(University of Parma), John Kirk(Université Paris-Saclay), Maryam Banikazemi(University of Alabama at Birmingham), Suma P. Shankar(Emory University), Seymour Packman(University of California, San Francisco), Majed Dasouki(University of Kansas), Carrolee Barlow(Merck & Co., Inc., Rahway, NJ, USA (United States)), Charles Marques Lourenço(Universidade de São Paulo), David J. Lockhart(Université Paris-Saclay), Usama Sharaf El Din(Université Paris-Saclay), C. Ronald Scott(University of Washington), Elfrida R. Benjamin(Université Paris-Saclay), Kathy Nicholls(Melbourne Health), Julie Yu(Hospital for Sick Children), David N. Finegold(University of Michigan–Ann Arbor), Özlem Göker-Alpan(Lysosomal and Rare Disorders Research and Treatment Center), Nina Skuban(Université Paris-Saclay), Ana Jovanović(Manchester Academic Health Science Centre), Pilar Giraldo(Université Paris-Saclay), Drago Bratkovic(Women's and Children's Hospital), Daniel G. Bichet(Hôpital du Sacré-Cœur de Montréal), Ulla Feldt‐Rasmussen(Copenhagen University Hospital), Stephen Waldek, Roberto Giugliani(Instituto de Biologia Molecular e Celular), Nicola Longo(University of Utah), Jeff Castelli(Université Paris-Saclay), Christopher Viereck(Université Paris-Saclay), Ahmad Tuffaha(Université Paris-Saclay), Jay Barth(Université Paris-Saclay), Franklin K. Johnson(Université Paris-Saclay), Khan Nedd(Université Paris-Saclay), Joel Charrow(Northwestern University), Hernan Amartino(Université Paris-Saclay)
New England Journal of Medicine
August 10, 2016
Cited by 555


Related Papers